16205-44-0Relevant articles and documents
Synthesis, characterization, optical properties, computational characterizations, QTAIM analysis and cyclic voltammetry of new organic dyes for dye-sensitized solar cells
Agheli, Zahra,Pordel, Mehdi,Beyramabadi, Safar Ali
, (2020)
In recent years, dye-sensitized solar cells (DSSCs) have regarded as potential solar cells for the next generation of photovoltaic technologies. Many organic compounds are explored and used in DSSCs to produce low-cost devices and improve the cell efficiency. In this work, three new heterocyclic purple dyes are synthesized from the reaction of 3-nitropyrazolo[1,5-a]pyridine with various arylacetonitriles for dye-sensitized solar cells (DSSCs), exhibiting high molar extinction coefficients and a broad absorption range led to the good photovoltaic performance of 6.95–7.18%. Physical spectral, analytical data and optical properties are established the structures of the new dyes. The optimized geometries and relevant frontier orbitals of the dyes are obtained by density functional theory (DFT) at the level of B3LYP/6-311 + G(d,p). Electrostatic potential maps and electron density maps of the dyes were also obtained by atoms in molecules (AIM) analysis. Cyclic voltammetry measurement was performed to evaluate the electrochemical properties of the dyes and reversible oxidation waves were observed for them.
Pyrido[1',2':1,5]pyrazolo[4,3-b]quinolines as New Fluorescent Heterocyclic Systems for Dye-Sensitized Solar Cells
Agheli, Z.,Beyramabadi, S. A.,Davoodnia, A.,Pordel, M.
, p. 1345 - 1350 (2020)
Abstract: New fluorescent heterocyclic compounds pyrido[1',2':1,5]pyrazolo[4,3-b]quinolines have been synthesized by the reaction of 3-nitropyrazolo[1,5-a]pyridine with different arylacetonitriles in high yield. Structural assignments of the new compounds
Preparation method of pyrazolo[1,5-a]pyridine derivative
-
Paragraph 0046-0054, (2021/04/21)
The invention discloses a preparation method of pyrazolo[1,5-a]pyridine derivatives, and belongs to the field of organic synthesis. The problems that an existing pyrazolo[1,5-a]pyridine structure synthesis method needs metal catalysis, the substrate range is limited, the total yield of multi-step reaction is low, stoichiometric additives, toxic oxidants and oxygen-free technologies are adopted, and reaction conditions are harsh are solved. The method comprises the steps: dissolving pyridinium salt, unsaturated alkene and 2,3-dichloro-5,6-dicyanobenzoquinone in an organic solvent, dropwise adding triethylamine to react, concentrating by a rotary evaporator to remove the solvent, and separating and purifying by silica gel column chromatography to obtain the pyrazolo[1,5-a]pyridine derivative.
Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties
Lee, Jung Wuk,Park, Jiwon,Kim, Jina,Kim, Jihyung,Choi, Changyu,Min, Kyung Hoon
, (2021/03/14)
Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1
2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof
-
Paragraph 0197; 0742-0744, (2020/03/03)
The invention relates to 2-pyridine substituted urea structural small molecule compounds as well as synthesis and application thereof. Specifically, the invention discloses the compounds represented by a formula (I) shown in the specification, enantiomers, diastereomers, racemates or a mixture of the compounds, or a pharmaceutically acceptable salt, hydrate and solvate of the compounds, a preparation method of the above materials, and applications of the above materials in preparation of an ASK1 small molecule inhibitor, or medicines for preventing and/or treating diseases related to ASK1, especially liver diseases, lung diseases, cardiovascular diseases, kidney diseases and metabolic diseases.
Azacycle diketone compound and preparation method thereof (by machine translation)
-
Paragraph 0550-0555, (2020/09/12)
The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)
Synthesis of pyrazol [1,5-alpha] pyridine-3-carboxylic acid derivatives
-
Paragraph 0064; 0079; 0080; 0081, (2019/02/04)
The invention relates to synthesis of pyrazol [1,5-alpha] pyridine-3-carboxylic acid derivatives, and belongs to the field of organic synthesis. Trimethylsulfonyl chloride is used as a raw material toreact with tert-butoxycarbonyl hydroxylamine to obtain a compound 3; then the compound 3 reacts with trifluoroacetic acid to obtain a mixed solution of a compound 4; the mixed solution directly reacts with pyrazine to obtain a compound 6 without carrying out separation, washing and drying; an ethyl propiolate reaction is continuously performed; a water phase obtained after the reaction is extracted by ethyl acetate; an organic extract obtained after extraction is dried by anhydrous MgSO4 and evaporated; remaining residues are subjected to recrystallization (ethyl acetate, methylbenzene or petroleum ether), separation, washing and drying to obtain a compound 8; the compound 8 further reacts with NaOH to obtain a compound 9. In the route, the second step and the third step are continuouslycarried out, so that not only is the risk of the process reduced, but also yield is over 70%. No matter whether the raw material is of a symmetrical structure, the target product can be accurately obtained. The synthesis is suitable for industrial production.
Regioselective Metalation and Functionalization of the Pyrazolo[1,5- a]pyridine Scaffold Using Mg- and Zn-TMP Bases
Balkenhohl, Moritz,Salgues, Bruno,Hirai, Takahiro,Karaghiosoff, Konstantin,Knochel, Paul
supporting information, p. 3114 - 3118 (2018/05/28)
A regioselective functionalization of the pyrazolo[1,5-a]pyridine scaffold using Mg- and Zn-TMP bases (TMP = 2,2,6,6-tetramethylpiperidyl) in the presence or absence of BF3·OEt2 is described. Also, various functionalized pyrazolo[1,5-a]pyridines bearing an ester function (and an NHBoc or ethyl group) are magnesiated and functionalized, leading to polysubstituted heterocycles. Additionally, a sulfoxide directed ortho-metalation, followed by the transition-metal-free amination of a pyrazolo[1,5-a]pyridine sulfoxide, using a magnesium amide, is reported.
Synthesis of Functionalized Pyrazolo[1,5-a]pyridines: [3+2] Cycloaddition of N-Aminopyridines and α,β-Unsaturated Carbonyl Compounds/Alkenes at Room Temperature
Ravi, Chitrakar,Samanta, Supravat,Mohan, Darapaneni Chandra,Reddy, N. Naresh Kumar,Adimurthy, Subbarayappa
, p. 2513 - 2522 (2017/05/22)
The synthesis of functionalized pyrazolo[1,5-a]pyridines through oxidative [3+2] cycloaddition of N-aminopyridines with α,β-unsaturated carbonyl compounds or electron-withdrawing olefins is described. The reactions proceed in N-methylpyrrolidone as the solvent under metal-free conditions at room temperature.
Novel urate anion transporter 1 (URAT1) inhibitors and application thereof in medicines
-
Paragraph 0099-0101, (2017/11/04)
The invention discloses novel urate anion transporter 1 (URAT1) inhibitors and application thereof in medicines. The novel URAT1 inhibitors are compounds shown in a formula (I) and pharmacologically acceptable salts of the compounds, wherein Y or Z is respectively and independently selected from N or CH; R1 or R2 is respectively and independently selected from H, D, halogen, cyano, hydroxyl, carboxyl, C1-4 alkyl, substituted C1-4 alkyl, C3-4 cycloalkyl, C1-4 alkoxy, substituted C1-4 alkoxy, phenyl, substituted phenyl, heterocyclic aryl or substituted heterocyclic aryl; R3 or R4 is respectively and independently selected from H or C1-3 alkyl, or R3 and R4 form 3-6-membered cycloalkyl together; R5 is H, C1-4 alkyl or substituted C1-4 alkyl. The compounds provided by the invention can be applied to preparation of uric acid excretion promoting medicines, and are especially used for medicines for treating or preventing hyperuricemia or gout. The formula (I) is described in the description.
